MacroGenics Doses First Patient in Phase 1 Trial of MGC030 for Advanced Solid Tumors
MacroGenics dosed the first patient in a Phase 1 trial of MGC030 for advanced solid tumors, announced Oct. 15, 2026. The antibody-drug conjugate becomes its third ADC in active clinical development. Preclinical findings showed encouraging antitumor activity; the clinical trial will assess safety, tolerability and preli